drugset
drugset / Trial / NCT07450313

The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT

NCT07450313 ↗

Phase 2 Not yet recruiting 20 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelSupportive care

Summary

This study aims to evaluate whether luspatercept can improve the efficacy and safety of anemia treatment in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation.

Timeline

Start
2026-03-14
Primary completion
2027-06-14
Completion
2027-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Luspatercept Protein / enzyme biologic 1 mg/kg Subcutaneous

Indications

disease related to hematopoietic stem cell transplant